Vaxcyte Non Current Liabilities Total from 2010 to 2024
| PCVX Stock | USD 91.70 3.16 3.57% |
Non Current Liabilities Total | First Reported 2019-12-31 | Previous Quarter 18.3 M | Current Value 18.3 M | Quarterly Volatility 34.8 M |
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 66.1 M, Interest Expense of 0.0 or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.16. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
Vaxcyte | Non Current Liabilities Total |
Latest Vaxcyte's Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Vaxcyte over the last few years. It is Vaxcyte's Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Vaxcyte Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 89,805,084 | |
| Geometric Mean | 47,834,859 | |
| Coefficient Of Variation | 60.40 | |
| Mean Deviation | 47,909,487 | |
| Median | 121,817,000 | |
| Standard Deviation | 54,245,917 | |
| Sample Variance | 2942.6T | |
| Range | 160.9M | |
| R-Value | (0.71) | |
| Mean Square Error | 1559.3T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | (8,644,925) | |
| Total Sum of Squares | 41196.7T |
Vaxcyte Non Current Liabilities Total History
About Vaxcyte Financial Statements
Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 22.1 M | 43.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.